{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-011123","form_type":"8-K","ticker":null,"cik":"0000849636","company_name":"RespireRx Pharmaceuticals Inc.","filed_at":"2023-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.428483+00:00","generated_at":"2026-06-17T05:31:37.573371+00:00","sec_items":["1.01","3.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"RespireRx raises $25,000 via sale of 250 shares of Series I 8% Redeemable Preferred Stock","bullets":["Raised $25,000 from two accredited investors for 250 shares of Series I 8% Redeemable Preferred Stock.","Series I Preferred Stock carries 8% annual dividend payable in shares; redeemable upon events like license payments ≥$15M.","Preferred stock is not convertible into common stock; transfer restricted except to family or affiliates.","As of April 4, 2023, common shares outstanding: 144,326,672.","Issuance exempt from registration under Section 4(a)(2) of the Securities Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-011123","json":"https://secwatch.observer/filing/0001493152-23-011123.json","markdown":"https://secwatch.observer/filing/0001493152-23-011123.md","text":"https://secwatch.observer/filing/0001493152-23-011123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/849636/000149315223011123/0001493152-23-011123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/849636/000149315223011123/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T05:31:37.573371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae067fa1383366dee0799b3557db9d555344306b","claim":"RespireRx Pharmaceuticals Inc.: Filed Certificate of Designation for Series I Preferred Stock to amend the certificate of incorporation, setting forth preferences, rights and limitations of the new series (effective 2023-04-03).","evidence_excerpt":"On April 3, 2023, the Company filed a Certificate of Designation, Preferences, Rights and Limitations of its Series I Preferred Stock, also referred to herein as the “Certificate” with the Secretary of State of the State of Delaware to amend the Company’s certificate of incorporation.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/849636/000149315223011123/0001493152-23-011123-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-04-03"}],"fact_type":"governance_change"},{"claim_id":"96adc69224f7f9cfed17a18ea76c5bae37c7bd0a","claim":"RespireRx Pharmaceuticals Inc. entered into Securities Purchase Agreement with two individual accredited investors investing jointly valued at $25,000.00 (effective 2023-04-05).","evidence_excerpt":"On April 5, 2023, RespireRx Pharmaceuticals Inc. (the “Company” or the “Corporation”) entered into a securities purchase agreement (“Securities Purchase Agreement) with two individual accredited investors investing jointly (“Investors”). Pursuant to the terms of the Securities Purchase Agreement, the investors invested $25,000.00 for 250 shares of Series I 8% Redeemable Preferred Stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/849636/000149315223011123/0001493152-23-011123-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"two individual accredited investors investing jointly"},{"label":"Value","value":"$25,000.00"},{"label":"Effective","value":"2023-04-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}